Background: Keratocystic odontogenic tumour and ameloblastoma are classified under tumours by WHO. tumour development and progression involves tumour suppressor genes and down regulation of onco-genes. Apoptosis inhibition is an important event in tumour formation which increases the life span of these cells. Aims and Objectives: To investigate the involvement of apoptosis inhibition in these lesions, expression of Bcl-2 was examined in 10 cases of KCOT (keratocystic odontogenic tumour) and ameloblastoma each. Our study revealed over-expression of Bcl-2 in all the cases in both tumours. The expression was analysed both qualitatively and quantitatively. Materials and Methods: 10 KCOT cases (sporadic parakeratinized KCOT n-9 and BCCNS KCOT n-1) and 10 Ameloblastoma cases (SMA n-9 and unicystic ameloblastoma n- 1) were selected. Immunohistochemical staining of Bcl-2 was carried out. • BCCNS(Basal cell carcinoma nevus syndrome) • SMA(Solid multicystic Ameloblastoma) • UA(Unicystic Ameloblastoma) Statistical Analysis: Differences in the mean scores for immunostain among the two types of lesions were analysed by students t test to compare the similarity or dissimilarity in the cell count of mean Bcl-2 expression between ameloblastoma and KCOT and their various layers. Results: : The intensity varied among the layers from intense to weak in basal / peripheral ameloblast- like cells and parabasal layers respectively and negative staining was seen only in superficial layer of KCOT but not in Ameloblastoma-central stellate reticulum-like cells in qualitative assessment. Quantitatively the basal layer/ peripheral ameloblast- like cells of both tumours had similar over expression while parabasal and central/superficial cells showed considerable differences. Our study indicates similar over-expression of bcl-2 in both the odontogenic lesions specifically basal layer / peripheral ameloblast- like cells which may represent tumorigenesis by escaping apoptosis. However does antiapoptotic activity and proliferative index warrant reclassification to tumour needs to be addressed.
IJCR is following an instant policy on rejection those received papers with plagiarism rate of more than 20%. So, All of authors and contributors must check their papers before submission to making assurance of following our anti-plagiarism policies.
